Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Therapy Name | Pazopanib |
| Synonyms | |
| Therapy Description |
Votrient (pazopanib) inhibits VEGFR-1, -2 and -3, KIT, and PDGFR, and FGFR1, 2, and 3, leading to decreased tumor angiogenesis and growth (PMID: 17620431, PMID: 23786770). Votrient (pazopanib) is approved for renal cell carcinoma and soft tissue sarcoma (FDA.gov). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Pazopanib | Votrient | GW-786034 | FGFR1 Inhibitor 26 FGFR2 Inhibitor 20 FGFR3 Inhibitor 17 KIT Inhibitor 55 PDGFR Inhibitor (Pan) 28 VEGFR Inhibitor (Pan) 33 | Votrient (pazopanib) inhibits VEGFR-1, -2 and -3, KIT, and PDGFR, and FGFR1, 2, and 3, leading to decreased tumor angiogenesis and growth (PMID: 17620431, PMID: 23786770). Votrient (pazopanib) is approved for renal cell carcinoma and soft tissue sarcoma (FDA.gov). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FGFR2 P253R | head and neck squamous cell carcinoma | predicted - sensitive | Pazopanib | Case Reports/Case Series | Actionable | In a clinical case study, treatment with Votrient (pazopanib) resulted in reduced tumor size in a patient with head and neck squamous cell carcinoma harboring FGFR2 P253R (PMID: 23786770). | 23786770 |
| FGFR3 S249C | renal pelvis transitional cell carcinoma | predicted - sensitive | Pazopanib | Clinical Study | Actionable | In a case study, a patient with urothelial carcinoma of the renal pelvis harboring FGFR3 S249C demonstrated a partial response lasting 9 months following treatment with Votrient (pazopanib) (PMID: 27271022). | 27271022 |
| FGFR2 K660N | Advanced Solid Tumor | sensitive | Pazopanib | Preclinical - Cell culture | Actionable | In a preclinical study, Votrient (pazopanib) inhibited growth of transformed cells expressing FGFR2 K660N in culture (PMID: 23786770). | 23786770 |
| FGFR1 amp | uterine carcinosarcoma | predicted - sensitive | Pazopanib | Case Reports/Case Series | Actionable | In a clinical case study, Votrient (pazopanib) treatment resulted in disease control for approximately 7 months in a patient with refractory uterine carcinosarcoma with FGFR1 amplification (PMID: 35586703). | 35586703 |
| FGFR2 S252W | gallbladder adenocarcinoma | predicted - sensitive | Pazopanib | Case Reports/Case Series | Actionable | In a clinical case study, Votrient (pazopanib) treatment resulted in stable disease lasting over 2 years in a patient with metastatic gallbladder adenocarcinoma harboring FGFR2 S252W (PMID: 36307559). | 36307559 |
| FGFR1 amp | Her2-receptor negative breast cancer | predicted - sensitive | Pazopanib | Case Reports/Case Series | Actionable | In a clinical case study, a patient with ERBB2 (HER2)-receptor negative breast cancer harboring FGFR1 amplification demonstrated antitumor activity when treated with Votrient (pazopanib), including a near complete loss of brain lesions and improved function of the liver (PMID: 29223982). | 29223982 |
| FGFR3 R248C | Advanced Solid Tumor | sensitive | Pazopanib | Preclinical - Cell culture | Actionable | In a preclinical study, Votrient (pazopanib) inhibited growth of transformed cells expressing FGFR3 R248C in culture (PMID: 23786770). | 23786770 |
| TP53 mutant | sarcoma | sensitive | Pazopanib | Clinical Study - Cohort | Actionable | In a retrospective analysis, advanced sarcoma patients with TP53 mutations displayed improved progression-free survival (208 vs 136 days, p=0.036) relative to patients with wild-type TP53 when treated with Votrient (pazopanib) (PMID: 26646755). | 26646755 |
| NRAS mutant | acute myeloid leukemia | predicted - resistant | Pazopanib | Preclinical - Patient cell culture | Actionable | In a preclinical study, NRAS mutations correlated with resistance to Votrient (pazopanib) in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627). | 30333627 |
| FGFR2 W290C | Advanced Solid Tumor | sensitive | Pazopanib | Preclinical - Cell culture | Actionable | In a preclinical study, Votrient (pazopanib) inhibited growth of transformed cells expressing FGFR2 W290C in culture (PMID: 23786770). | 23786770 |
| FGFR2 K660E | Advanced Solid Tumor | sensitive | Pazopanib | Preclinical - Cell culture | Actionable | In a preclinical study, Votrient (pazopanib) inhibited growth of transformed cells expressing FGFR2 K660E in culture (PMID: 23786770). | 23786770 |
| FGFR2 F276C | intrahepatic cholangiocarcinoma | predicted - sensitive | Pazopanib | Case Reports/Case Series | Actionable | In a clinical case study, Votrient (pazopanib) treatment resulted in a partial response that continued for 11 months after starting treatment in a patient with intrahepatic cholangiocarcinoma harboring FGFR2 F276C (PMID: 34480077). | 34480077 |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT01407562 | Phase I | Carboplatin Paclitaxel Pazopanib | Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors | Terminated | USA | 0 |
| NCT02956798 | Phase II | Pazopanib | Pazopanib Vs. Local Therapy for Renal Cancer With Metastases | Active, not recruiting | USA | 0 |
| NCT01466972 | Phase II | Pazopanib | Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib | Completed | USA | 0 |
| NCT02645149 | Phase II | Trametinib Pazopanib Ceritinib Ribociclib + Trametinib | Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma (MatchMel) | Recruiting | 1 | |
| NCT04741438 | Phase III | Ipilimumab + Nivolumab Pazopanib | Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype (RAR-Immune) | Recruiting | FRA | 0 |
| NCT02601209 | Phase Ib/II | Pazopanib Sapanisertib | Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma | Terminated | USA | 0 |
| NCT01468922 | Phase I | Tivantinib Pazopanib | Pazopanib and ARQ 197 for Advanced Solid Tumors | Completed | USA | 0 |
| NCT02300545 | Phase II | Pazopanib | Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy | Completed | USA | 0 |
| NCT01956669 | Phase II | Pazopanib | Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors | Completed | USA | FRA | ESP | CAN | 3 |
| NCT02406521 | Phase I | Pazopanib Radium Ra 223 dichloride Sorafenib | Exploratory Study of Radium-223 and Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Metastases | Completed | USA | 0 |
| NCT01392183 | Phase II | Diphenhydramine Temsirolimus Pazopanib | Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC) | Completed | USA | 0 |
| NCT01759303 | Phase II | Pazopanib | Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung | Terminated | USA | 0 |
| NCT04199026 | Phase I | Irinotecan Doxorubicin Ifosfamide Temozolomide Temsirolimus Ganitumab Pazopanib Everolimus Vincristine Sulfate | Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma | Not yet recruiting | USA | 0 |
| NCT02049905 | Phase III | Dacarbazine Doxorubicin Ifosfamide Pazopanib Aldoxorubicin Docetaxel + Gemcitabine | Phase 3 Study to Treat Patients With Soft Tissue Sarcomas | Completed | USA | ITA | FRA | ESP | CAN | 8 |
| NCT02014636 | Phase I | Pazopanib Pembrolizumab | Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC) | Completed | USA | 1 |
| NCT01575548 | Phase III | Pazopanib | Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery | Active, not recruiting | USA | 0 |
| NCT01832259 | Phase II | Pazopanib | A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection | Completed | USA | 0 |
| NCT01236547 | Phase II | Paclitaxel Pazopanib | Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer | Completed | USA | 0 |
| NCT02180867 | Phase II | Pazopanib Doxorubicin + Ifosfamide | Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can be Removed by Surgery (PAZNTIS) | Active, not recruiting | USA | CAN | 1 |
| NCT02560012 | Phase II | Everolimus Sorafenib Temsirolimus Axitinib Sunitinib Pazopanib | Personalized Targeted Inhibitors Treatment in Renal Cell Cancer | Terminated | USA | 0 |
| NCT01599832 | Phase I | Pazopanib | Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer | Terminated | USA | 0 |
| NCT01217931 | Phase II | Everolimus Pazopanib Bevacizumab | Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy | Active, not recruiting | USA | 0 |
| NCT01841736 | Phase II | Pazopanib | Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors | Active, not recruiting | USA | CAN | 0 |
| NCT01339871 | Phase I | Vorinostat Pazopanib | Phase I Study of Pazopanib and Vorinostat | Completed | USA | 0 |
| NCT01158521 | Phase II | Pazopanib | Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer | Completed | USA | 0 |
| NCT02029001 | Phase II | Durvalumab + Tremelimumab Olaparib Pazopanib Nilotinib | Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: My Own Specific Treatment (MOST plus) | Recruiting | FRA | 0 |
| NCT03592472 | Phase III | Pazopanib Abexinostat + Pazopanib | A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) | Recruiting | USA | ITA | ESP | 3 |
| NCT02307474 | Phase I | Pazopanib | A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer | Withdrawn | USA | 0 |
| NCT01462630 | Phase II | Pazopanib | Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma | Completed | USA | 0 |
| NCT01221506 | Phase I | Pazopanib | Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC) | Completed | USA | 0 |
| NCT01361113 | Phase II | Pazopanib | Neoadjuvant Pazopanib in Renal Cell Carcinoma | Completed | USA | 0 |
| NCT01330966 | Phase II | Pazopanib | Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma | Completed | USA | 1 |
| NCT03334409 | Phase II | Pazopanib | Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery | Terminated | USA | 0 |
| NCT01767636 | Phase II | Pazopanib | Pazopanib in Treating Patients With Metastatic Non-Clear Cell Kidney Cancer | Active, not recruiting | USA | 0 |
| NCT02009449 | Phase I | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin Nab-paclitaxel | A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
| NCT02979899 | Phase III | Pazopanib Carotuximab + Pazopanib | A RANDOMIZED PHASE 3 TRIAL OF TRC105 AND PAZOPANIB VERSUS PAZOPANIB ALONE IN PATIENTS WITH ADVANCED ANGIOSARCOMA (TAPPAS) | Completed | USA | ITA | FRA | ESP | DEU | AUT | 2 |
| NCT01582204 | Phase I | Pazopanib Sunitinib | Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma | Active, not recruiting | USA | 0 |
| NCT02551718 | Phase I | Bosutinib Irinotecan Romidepsin Busulfan Melphalan Nilotinib Crizotinib Cytarabine Mitoxantrone Dasatinib Pazopanib Paclitaxel Clofarabine Hydroxyurea Tretinoin Carfilzomib Nelarabine Bexarotene Pentostatin Everolimus Cabozantinib Mercaptopurine Methotrexate Cladribine Thioguanine Daunorubicin Ponatinib Etoposide Afatinib Gefitinib Gemcitabine Regorafenib Arsenic trioxide Trametinib Imatinib Erlotinib Dabrafenib Decitabine Axitinib Azacitidine Ruxolitinib Fludarabine Lapatinib Ceritinib Sirolimus Sorafenib Lomustine Sunitinib Cabazitaxel Temsirolimus Topotecan Bortezomib Pralatrexate | High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia | Completed | USA | 0 |
| NCT03200717 | Phase II | Pazopanib | Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment | Completed | USA | FRA | ESP | DEU | CAN | AUT | 5 |
| NCT02729194 | Phase I | Pazopanib | Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma | Completed | USA | 0 |
| NCT01552356 | Phase I | Pazopanib | Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors | Active, not recruiting | USA | 0 |
| NCT01506596 | Phase II | Pazopanib | Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma | Completed | USA | 0 |
| NCT02203760 | Phase II | Pazopanib Gemcitabine + Pazopanib | Pazopanib vs. Pazopanib Plus Gemcitabine (PazoDoble) | Recruiting | DEU | 0 |
| NCT02193152 | Phase I | Pazopanib | Pazopanib in Molecularly Selected Patients With Advanced NSCLC | Terminated | USA | 0 |
| NCT02788201 | Phase II | Erlotinib Thiotepa Imatinib Dacarbazine Arsenic trioxide Idarubicin Mitomycin C Thioguanine Mercaptopurine Methotrexate Cladribine Epirubicin Gemcitabine Doxorubicin Bleomycin Etoposide Gefitinib Daunorubicin Lomustine Sorafenib Sunitinib Ifosfamide Asparaginase Ixabepilone Abiraterone Azacitidine Ruxolitinib Decitabine Axitinib Estramustine Floxuridine Lapatinib Carmustine Fludarabine Nilotinib Cisplatin Vismodegib Vandetanib Melphalan Busulfan Carboplatin Toremifene Crizotinib Dactinomycin Temsirolimus Vorinostat Romidepsin Fluorouracil Irinotecan Bortezomib Tamoxifen Topotecan Chlorambucil Pentostatin Eribulin Carfilzomib Vemurafenib Hydroxyurea Exemestane Vincristine Sulfate Dasatinib Mitoxantrone Vinblastine Cytarabine Tretinoin Clofarabine Teniposide Docetaxel Pazopanib Oxaliplatin Streptozocin Paclitaxel Bendamustine Mechlorethamine Mitotane | Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma | Completed | USA | 0 |
CKB BOOST